Switch theme
Sign up to access all valuation multiples
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
1999
299
LTM Revenue $12.7M
LTM EBITDA -$240M
$283M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rocket Pharmaceuticals has a last 12-month revenue of $12.7M and a last 12-month EBITDA of -$240M.
In the most recent fiscal year, Rocket Pharmaceuticals achieved revenue of n/a and an EBITDA of -$247M.
Rocket Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rocket Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$237M | -$247M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$222M | -$246M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Rocket Pharmaceuticals's stock price is $6.
Rocket Pharmaceuticals has current market cap of $630M, and EV of $283M.
See Rocket Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $283M | $630M | XXX | XXX | XXX | XXX | $-2.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Rocket Pharmaceuticals has market cap of $630M and EV of $283M.
Rocket Pharmaceuticals's trades at 22.4x LTM EV/Revenue multiple, and -1.2x LTM EBITDA.
Analysts estimate Rocket Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Rocket Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $283M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.1x | XXX | XXX | XXX |
| P/E | -2.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRocket Pharmaceuticals's NTM/LTM revenue growth is 468%
Rocket Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Rocket Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Rocket Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Rocket Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rocket Pharmaceuticals acquired XXX companies to date.
Last acquisition by Rocket Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Rocket Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Rocket Pharmaceuticals founded? | Rocket Pharmaceuticals was founded in 1999. |
| Where is Rocket Pharmaceuticals headquartered? | Rocket Pharmaceuticals is headquartered in United States of America. |
| How many employees does Rocket Pharmaceuticals have? | As of today, Rocket Pharmaceuticals has 299 employees. |
| Who is the CEO of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's CEO is Dr. Gaurav Shah, M.D.. |
| Is Rocket Pharmaceuticals publicy listed? | Yes, Rocket Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Rocket Pharmaceuticals? | Rocket Pharmaceuticals trades under RCKT ticker. |
| When did Rocket Pharmaceuticals go public? | Rocket Pharmaceuticals went public in 2015. |
| Who are competitors of Rocket Pharmaceuticals? | Similar companies to Rocket Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's current market cap is $630M |
| What is the current revenue of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's last 12-month revenue is $12.7M. |
| What is the current EBITDA of Rocket Pharmaceuticals? | Rocket Pharmaceuticals's last 12-month EBITDA is -$240M. |
| What is the current EV/Revenue multiple of Rocket Pharmaceuticals? | Current revenue multiple of Rocket Pharmaceuticals is 22.4x. |
| What is the current EV/EBITDA multiple of Rocket Pharmaceuticals? | Current EBITDA multiple of Rocket Pharmaceuticals is -1.2x. |
| Is Rocket Pharmaceuticals profitable? | Yes, Rocket Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
